Craig-Hallum Assumes Guardant Health at Buy, Announces Price Target of $28
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Alex Nowark assumes coverage on Guardant Health (NASDAQ:GH) with a Buy rating and sets a price target of $28.
April 24, 2024 | 5:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guardant Health receives a Buy rating from Craig-Hallum with a price target of $28.
Analyst ratings, especially from reputable firms like Craig-Hallum, can significantly influence investor sentiment and stock prices. A Buy rating combined with a specific price target provides a positive outlook for Guardant Health, suggesting potential upside based on the analyst's research. This could lead to increased investor interest and potentially higher stock prices in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100